Benzoyl peroxide
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1984
- First approval year
- 1984
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Benzoyl peroxide
- Molecular weight
- 242.23
- Structure (SMILES)
- O=C(OOC(=O)c1ccccc1)c1ccccc1
- acetoxyl 2 5
- Acetoxyl 2.5
- acetoxyl 5
- Acetoxyl 5
- acnecide
- Acnecide
- acnecide 10
- Acnecide 10
- acnegel
- Acnegel
- acnegel fte
- Acnegel fte
- acnidazil
- Acnidazil
- benoxyl 10
- Benoxyl 10
- benoxyl 20
- Benoxyl 20
- benoxyl 5
- Benoxyl 5
- benzagel 10
- Benzagel 10
- benzagel 5
- Benzagel 5
- benzamycin
And 81 more, listed on the interactive page.
- acanya component benzoyl peroxide
- ACANYA COMPONENT BENZOYL PEROXIDE
- adapalene and benzoyl peroxide
- anhydrous benzoyl peroxide
- Anhydrous benzoyl peroxide
- benzaclin component benzoyl peroxide
- BENZACLIN COMPONENT BENZOYL PEROXIDE
- benzamycin component benzoyl peroxide
- BENZAMYCIN COMPONENT BENZOYL PEROXIDE
- benzoyl peroxide
- Benzoyl peroxide
- Benzoyl Peroxide
- BENZOYL PEROXIDE [FCC]
- BENZOYL PEROXIDE [HSDB]
- BENZOYL PEROXIDE [IARC]
- BENZOYL PEROXIDE [JAN]
- BENZOYL PEROXIDE [MART.]
- BENZOYL PEROXIDE [MI]
- BENZOYL PEROXIDE [ORANGE BOOK]
- BENZOYL PEROXIDE [USAN]
- BENZOYL PEROXIDE [USP IMPURITY]
- BENZOYL PEROXIDE [VANDF]
- Benzoyl peroxide [WHO-DD]
- benzoyl peroxide anhydrous
- Benzoyl peroxide anhydrous
And 50 more, listed on the interactive page.
- CAS registry numbers
- 94-36-0
- ChEMBL ID
- CHEMBL1200370
- InChIKey
- OMPJBNCRMGITSC-UHFFFAOYSA-N
- PubChem compound IDs
- 7187
- RxNorm IDs (RxCUI)
- 1418
- FDA ingredient codes (UNII)
- W9WZN9A0GM
- D10AE01
- D10AE51
Sources for recorded values
- Applicant
- BAUSCH
- Approval date
- 23 Oct 2008
- Application number
- NDA050819
- Patents
- 14
- Designations
- 0
- Earliest recorded loss of exclusivity
- 23 May 2041
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
Administration routes
- topical
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Keratosis, Actinic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002496
- Subject identifier
- D055623
- Condition
- Acne Vulgaris
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003894
- Subject identifier
- D000152
- Condition
- Molluscum Contagiosum
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007375
- Subject identifier
- D008976
- Condition
- Rosacea
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000760
- Subject identifier
- D012393
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002496
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003894
- Condition identifier
- EFO_0007375
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000760
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005855
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006559
- Condition identifier
- MONDO_0006604
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011438
- Highest recorded phase
- 4
- Event
- acne
- Reports
- 11
- Reporting signal score
- 22.8987
- Event
- acne fulminans
- Reports
- 2
- Reporting signal score
- 9.68672
- Event
- angioedema
- Reports
- 13
- Reporting signal score
- 15.9008
- Event
- application site burn
- Reports
- 8
- Reporting signal score
- 32.6088
- Event
- application site discolouration
- Reports
- 4
- Reporting signal score
- 14.692
- Event
- application site dryness
- Reports
- 3
- Reporting signal score
- 12.8011
- Event
- application site erythema
- Reports
- 17
- Reporting signal score
- 57.1103
- Event
- application site exfoliation
- Reports
- 5
- Reporting signal score
- 21.8653
- Event
- application site inflammation
- Reports
- 2
- Reporting signal score
- 7.64493
- Event
- application site irritation
- Reports
- 4
- Reporting signal score
- 11.1534
- Event
- application site pain
- Reports
- 11
- Reporting signal score
- 30.6434
- Event
- application site paraesthesia
- Reports
- 2
- Reporting signal score
- 9.32734
- Event
- application site pruritus
- Reports
- 10
- Reporting signal score
- 31.5908
- Event
- application site rash
- Reports
- 5
- Reporting signal score
- 13.7314
- Event
- application site swelling
- Reports
- 8
- Reporting signal score
- 34.2139
- Event
- application site warmth
- Reports
- 2
- Reporting signal score
- 8.69865
- Event
- broncholithiasis
- Reports
- 3
- Reporting signal score
- 20.9417
- Event
- burning sensation
- Reports
- 8
- Reporting signal score
- 9.00386
- Event
- burns second degree
- Reports
- 4
- Reporting signal score
- 15.8864
- Event
- chemical burn of skin
- Reports
- 3
- Reporting signal score
- 15.0284
- Event
- choroiditis
- Reports
- 10
- Reporting signal score
- 53.6088
- Event
- dermatitis
- Reports
- 9
- Reporting signal score
- 20.099
- Event
- dermatitis allergic
- Reports
- 10
- Reporting signal score
- 24.7533
- Event
- dermatitis contact
- Reports
- 13
- Reporting signal score
- 41.9047
- Event
- diarrhoea
- Reports
- 1
- Reporting signal score
- 9.35499
And 30 more, listed on the interactive page.
- NCT00151541
- NCT00377000
- NCT00421993
- NCT00422240
- NCT00441415
- NCT00446043
- NCT00658112
- NCT00663286
- NCT00664248
- NCT00671749
- NCT00687908
- NCT00713609
- NCT00757523
- NCT00776919
- NCT00807014
- NCT00837213
- NCT00841776
- NCT00869492
- NCT00877409
- NCT00887484
- NCT00891982
- NCT00907257
- NCT00913185
- NCT00919191
- NCT00926367
And 60 more, listed on the interactive page.
- How often
- Once daily, then up to three times daily
- Apply a thin layer to the affected area
- Cover the entire affected area
- Reduce application if dryness or peeling occurs
- Start with once daily, then increase as needed
- Stop use and consult a doctor if irritation occurs
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 0
- Polar surface area
- 52.6
- Calculated partition coefficient (ALogP)
- 2.62
- Calculated partition coefficient (XLogP)
- 3.5
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 18
- Molecular formula
- C14H10O4
- Monoisotopic mass
- 242.05790880
- Natural product
- Yes
- 0187-0006
- 0187-3050
- 0299-5906
- 0299-5945
- 0480-3154
- 13548-132
- 16714-984
- 21922-022
- 21922-052
- 21922-074
- 43538-176
- 45802-383
- 45802-597
- 45802-736
- 45802-846
- 45802-853
- 46708-662
- 51862-771
- 51862-772
- 59651-604
- 62332-662
- 64980-328
- 68308-127
- 68308-662
- 68462-301
And 24 more, listed on the interactive page.
- Recorded assays
- 979
- Active assays
- 12
- Confirmatory
- Other
- Summary
- Dermatologic Agents
Related records
Trials (87)
- "A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients."
- 2940nm Er:YAG Laser Versus Benzoyl Peroxide Gel for the Treatment of Inflammatory Acne
- A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris
- A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
- A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
- A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
- A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
- A Novel Method to Improve Acne Outcomes
- A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%
- A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
- A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels.
- A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris
- A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
- A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
- A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris
- A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
- A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne
- A Study of Different Use Regimens Using Two Acne Treatments
- A Study of Efficacy of Benzoyl Peroxide Regimens in Treatment of Unpleasant Foot Odor
- A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris
Approved for (1)
In development for (3)
- Actinic keratosis Phase 2
- Molluscum contagiosum Phase 3
- Rosacea Phase 1